Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334396 | 0.74 | GRM5 (0.34) | SMYD2GRM5GRM1 | |
| SCHEMBL6335783 | 0.70 | BCHE (0.39) | SMYD2GRM5GRM1 | |
| SCHEMBL2914349 | 0.68 | RIPK1 (0.41) | SMYD2GRM5GRM1 | |
| SCHEMBL23670531 | 0.67 | SMYD2 (0.43) | SMYD2GRM5GRM1 | |
| SCHEMBL29552957 | 0.67 | SMYD2 (0.43) | SMYD2GRM5GRM1 | |
| SCHEMBL19285174 | 0.67 | SMYD2 (0.43) | SMYD2GRM5GRM1 | |
| SCHEMBL10380887 | 0.66 | SMYD2 (0.39) | SMYD2 | |
| SCHEMBL3143701 | 0.66 | CMA1 (0.39) | SMYD2 | |
| SCHEMBL22554979 | 0.65 | SMYD2 (0.40) | SMYD2GRM5GRM1 | |
| SCHEMBL25906381 | 0.65 | CHRNB2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | SMYD2 1618/4885GRM5 3856/4885GRM1 3202/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | SMYD2 1826/4885GRM5 4252/4885GRM1 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.